Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference72 articles.
1. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet];Ferlay,2013
2. Systemic treatment for BRAF-mutant melanoma: where do we go next?;Menzies;Lancet Oncol,2014
3. Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets;Flaherty;Clin Exp Metastasis,2012
4. BRAF targeted therapy changes the treatment paradigm in melanoma;Ribas;Nat Rev Clin Oncol,2011
5. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011
Cited by 169 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors;Cancers;2024-08-27
2. Liquid biopsy for diagnostic and prognostic evaluation of melanoma;Frontiers in Cell and Developmental Biology;2024-08-02
3. Alantolactone enhances the sensitivity of melanoma to MAPK pathway inhibitors by targeting inhibition of STAT3 activation and down-regulating stem cell markers;Cancer Cell International;2024-05-31
4. Specific BCG-related gene expression levels correlate with immune cell infiltration and prognosis in melanoma;Journal of Leukocyte Biology;2024-03-13
5. Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer;British Journal of Cancer;2024-01-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3